HYPORTH

New approaches in the development of Hypoallergenic implant material in Orthopaedics: steps to personalised medicine

Coordinatore	OTTO-VON-GUERICKE-UNIVERSITAET MAGDEBURG    more  Organization address address: UNIVERSITAETSPLATZ 2 city: MAGDEBURG postcode: 39106 contact info Titolo: Mr. Nome: Sigmar Cognome: Beust Email: send email Telefono: +49 3916715076 Fax: +49 391 67 15075
Nazionalità Coordinatore	Germany [DE]
Totale costo	7˙201˙662 €
EC contributo	5˙282˙600 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2013-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-08-01   -   2018-07-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	OTTO-VON-GUERICKE-UNIVERSITAET MAGDEBURG  Organization address address: UNIVERSITAETSPLATZ 2 city: MAGDEBURG postcode: 39106 contact info Titolo: Mr. Nome: Sigmar Cognome: Beust Email: send email Telefono: +49 3916715076 Fax: +49 391 67 15075	DE (MAGDEBURG)	coordinator	1˙350˙807.00
2	TARTU ULIKOOL  Organization address address: ULIKOOLI 18 city: TARTU postcode: 50090 contact info Titolo: Dr. Nome: Aare Cognome: Märtson Email: send email Telefono: +372 7318280 Fax: 3727318285	EE (TARTU)	participant	900˙000.00
3	PROGENIKA BIOPHARMA SA  Organization address address: "Parque Tecnologico de Zamudio, Edificio 801 -A-, Planta 2" city: DERIO - VIZCAYA postcode: 48160 contact info Titolo: Dr. Nome: Sergio Cognome: Escorza Email: send email Telefono: +34 944064525 Fax: +34 94 406 45 26	ES (DERIO - VIZCAYA)	participant	750˙928.00
4	RESEARCH CENTRE FOR NATURAL SCIENCES, HUNGARIAN ACADEMY OF SCIENCES  Organization address address: PUSZTASZERI UTCA 59-67 city: BUDAPEST postcode: 1025 contact info Titolo: Dr. Nome: Katalin Cognome: Balázsi Email: send email Telefono: +36 13922249 Fax: +361 392 2226	HU (BUDAPEST)	participant	709˙999.00
5	MATHYS AG BETTLACH  Organization address address: ROBERT MATHYS STRASSE 5 city: BETTLACH postcode: 2544 contact info Titolo: Dr. Nome: Daniel Cognome: Delfosse Email: send email Telefono: +41 326441586	CH (BETTLACH)	participant	455˙199.00
6	INSTYTUT OBROBKI PLASTYCZNEJ  Organization address address: Jana Pawla II 14 city: Poznan postcode: 61-139 contact info Titolo: Mrs. Nome: Joanna Cognome: Bednarczyk Email: send email Telefono: +48 616570555	PL (Poznan)	participant	404˙291.00
7	GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG GAB O  Organization address address: Oskar-von-Miller-Ring 29 city: MUENCHEN postcode: 80333 contact info Titolo: Ms. Nome: Birgit Cognome: Fuchs Email: send email Telefono: +49 892881040 Fax: +49 8928810420	DE (MUENCHEN)	participant	400˙000.00
8	TEKNOLOGISK INSTITUT  Organization address address: GREGERSENSVEJ 1 city: TAASTRUP postcode: 2630 contact info Titolo: Dr. Nome: Mikael Cognome: Poulsen Email: send email Telefono: +45 72201861 Fax: +45 72201870	DK (TAASTRUP)	participant	311˙376.00
9	MAGYAR TUDOMANYOS AKADEMIA ENERGIATUDOMANYI KUTATOKOZPONT  Organization address address: KONKOLY THEGE MIKLOS UT 29-33 city: Budapest postcode: 1121 contact info Titolo: Dr. Nome: Krisztina Cognome: Szakolczai Email: send email Telefono: +36 1 392 2222 3362	HU (Budapest)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Europe is confronted by a demographic challenge as a decreasing work force has to support an increasing elderly population. The economic risk implied by this burden could be addressed by efforts to achieve an increase in Healthy Life Years. One key element would be to ensure unrestricted mobility for especially the elderly, allowing them to stay at work for longer. Irreversible joint deterioration often requires a joint replacement. Implantation of artificial joints is one of the most successful orthopaedic interventions. However, an increasing number of patients receive revision surgery with these 10 % of these contract an infection and 50 % develop an adverse immune reaction (AIR) to conventional implant material. At the moment the reasons for the development of AIR are inadequately understood. Our proposal contains innovative solutions concerning this problem. A predictive approach using biomarkers will identify patients with risk to develop AIR. These patients will receive hypoallergenic endoprostheses, avoiding AIR to conventional material. Novel hypoallergenic material combinations will be developed in the frame of this consortium by material scientists and implant manufacturer. Via immunological, microbiological and biocompatibility testing the development and production process will be improved constantly. The matching of implant material with the allergenic background of patients will avoid complicated and cost-intensive reverse reactions and is a step towards personalised medicine. A further approach is to achieve a better understanding of mechanisms of AIR, and its faster and easier diagnosis using sensitive diagnostic biomarkers for an accurate differentiation from low-grade infection. Additionally, mathematical modelling of results from different methods will show us the gene regulatory network that leads to an amplification of the adverse immune response triggered by prosthetic implants and will develop predictive models of AIR process.'